The Medicines Co. Newsletter
-
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program
22 Oct 2025 15:19 GMT
… : ARCT), a commercial messenger RNA medicines company focused on the development of …
-
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
21 Oct 2025 23:05 GMT
… clinical-stage diabetes and obesity medicines company focused on the development of …
-
Blacksmith Medicines Co-Founder Presents At The 21St International Conference On Biological Inorganic Chemistry
01 Aug 2025 17:10 GMT
(MENAFN- PR Newswire)
Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Blacksmith Medicines, Inc. ( …
-
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
13 Jan 2025 14:00 GMT
… become a diabetes and obesity medicines company. Based on the most recent …
-
Biotechs Chroma, Nvelop merge to form genetic medicines company
11 Dec 2024 12:29 GMT
-
Frontier Medicines Announces Third Precision Oncology Development Candidate
14 Oct 2025 11:00 GMT
… Corporation, a clinical-stage precision medicines company unlocking the proteome to develop …
-
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
14 Oct 2025 11:00 GMT
… : PASG), a clinical stage genetic medicines company focused on improving the lives … ) is a clinical stage genetic medicines company on a mission to improve …
-
Next-Generation Therapy Market Growth, Trends and Competitive Strategies – Towards Healthcare
13 Oct 2025 16:00 GMT
… Biotherapeutics, a leading global genetic medicines company, launched Rare Therapeutics, Inc., a …
-
Layoffs hit another Massachusetts genetic medicines company
14 Oct 2024 17:50 GMT
-
Alnylam's founding CEO is back with another RNAi-based medicines company
08 Oct 2024 17:00 GMT